- Prescribing Information
- For US Patients
DARZALEX® (daratumumab) is a prescription medicine used to treat a type of blood cancer called multiple myeloma. DARZALEX® is not chemotherapy. It is a targeted monoclonal antibody that helps slow or stop the progression of multiple myeloma in several ways.
One way is by attaching itself to multiple myeloma cells in your body. To be specific, DARZALEX® attaches to a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
By doing this, DARZALEX® directly kills the multiple myeloma cells, and/or allows your immune system to destroy them. Because DARZALEX® targets the CD38 protein, it may also affect other cells with this protein on their surface.
Multiple myeloma cells can go unrecognized by your body, which allows them to grow.
DARZALEX® attaches itself to the CD38 protein on the
surface of multiple myeloma cells, as well as on
certain other types of cells, such as red blood cells.
DARZALEX® directly kills multiple myeloma cells
and/or allows your immune system to identify and
destroy them. Because of the way DARZALEX®
works, it may also affect normal cells.
Your doctor will discuss a specific treatment plan with DARZALEX® depending on whether you’re newly diagnosed or have had prior treatments:
Learn about DARZALEX® + Velcade® (bortezomib) + melphalan + prednisone combination therapy
Learn about DARZALEX® + Revlimid® (lenalidomide) + dexamethasone combination therapyLearn about DARZALEX® + Velcade® (bortezomib) + dexamethasone combination therapy
Learn about DARZALEX® + Pomalyst® (pomalidomide) + dexamethasone combination therapy
Your healthcare provider will develop a treatment plan that is suited to your needs. If you have questions about your regimen, follow up with your doctor.
